KNSA Q1 2018 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$16M

Net Income

-$16M

EPS (Diluted)

$-0.34

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$558,000

Balance Sheet

Total Assets

$225M

Total Liabilities

$19M

Stockholders' Equity

$205M

Cash & Equivalents

$221M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$16M	-$5M	-223.7%
Net Income	-$16M	-$5M	-223.5%